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STUDY OVERVIEW

Objectives
The objectives of this study are to describe the characteristics, current management and health outcomes of people with perianal abscess and the impact on their lives (the focus is the post-operative perianal abscess cavity), with the aim of addressing the following research questions:
 What level of pain is experienced after incision and drainage of a perianal abscess?  How often do significant events (such as complete wound healing, abscess recurrence, re-operation and fistula-in-ano) occur in people with a perianal abscess cavity  What treatments do people with a perianal abscess cavity receive?  What is the health-related quality of life (including pain) of people with a perianal abscess cavity?
 What is the cost of caring for people with a perianal abscess cavity to the NHS?
Outcome Measures
The outcome measures for the study are:
 Average pain score and worst daily pain score during the first week after perianal abscess incision and drainage (may also include pain pre/during and after dressing changes). This study has been designed to gather data to inform the choice of primary and secondary endpoints for a future clinical trial. It is therefore unnecessary to have a hierarchy of endpoints.
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Study Outline
Figure 1: Study Outline
A flow diagram outlining the outline of the study is provided STRICTLY CONFIDENTIAL ST001_TEMP1/4
Study Design
This is a multi-centre, prospective observational feasibility study. The principles of Good Clinical Practice (GCP) are adhered to. The study will aim to recruit 150 patients over a 10 month period to evaluate outcomes and demonstrate feasibility for a full study.
Patient Population Inclusion Criteria:
 All patients undergoing incision and drainage of primary perianal abscess as an emergency.
Exclusion Criteria:
 Patient less than 18 years of age.  Patients in whom the abscesses are sequelae of concurrent disease or trauma.  Patients in whom Fournier's gangrene is suspected.  Patients unable to give informed consent.  Patients in whom the abscess crosses the midline (horseshoe abscess). 
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DESCRIPTION OF BASELINE SUBJECT CHARACTERISTICS
This section details the baseline demographics of the patient population at the point of randomisation. Numeric data are presented as medians with associated interquartile ranges. Categorical data are presented as frequency counts with associated percentages. 
WITHDRAWALS & LOSSES TO FOLLOW-UP
Reason for ending treatment Overall
Lost to follow-up 3 Withdrew consent 1 Other* 2 Total withdrawn from trial Days from randomisation to withdrawal from treatment 39 (28, 54) median (IQR), n *Other here denotes patients who have withdrawn from study without any further information as to why they are removed from the study. Table 6 :
Efficacy Analysis
PAIN SCORE
Estimated Pain score across time Table 6 gives the median (Inter-quartile range) of pain before, during and after treatment across the first three weeks. Pain score profiles Figure 3 details the pain score profiles for each patient across time with estimated mean profiles at 1, 2, 3, 4, 5, 6, 7, 21 and 28 days. 
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